Details for Patent: 6,576,659

Executive summary US 6,576,659 covers a method of using oxandrolone to treat specific skin wounds in patients, with claim scope anchored on (1) wound types (burn, ulcer, skin graft) and (2) administration modes (oral or topical), with dependent claims adding specific ulcer subtypes, dosing ranges (about 1 to 100 mg/day; exemplified at 20 mg/day and 80 mg/day), and formulation/kinetic options (solid, liquid, sustained-release). A separate claim branch covers “burn-induced weight loss” treated by oxandrolone administered orally or topically in conjunction with a protein supplement, again tied to wound/burn context and the same dosing/formulation variants. The patent’s practical enforceability in the US is strongest against direct method-of-treatment conduct (use by clinicians and resulting commercial products when tied to a label or instructions), and weaker against purely incidental oxandrolone exposure without the claimed wound indication, burn context, protein-supplement combination, and route/formulation constraints.

US Patent 6,576,659 method claims: what is the scope of oxandrolone for skin wounds in the US?

US 6,576,659 claim set is drafted as a use patent (method-of-treatment) for oxandrolone, not as a composition patent. The claim language is “administering” oriented, which makes the enforceable act typically the “use” of oxandrolone in accordance with the method steps, rather than manufacture or formulation alone.

What patients and indications does US 6,576,659 cover?

The independent claim (Claim 1) limits the patient group by clinical condition and requires a qualifying wound selection:

• Skin wound selected from: burn, ulcer, skin graft
• Patient “suffering from the skin wound”
• Method requires administering oxandrolone orally or topically in a therapeutically effective amount

The dependent claim structure creates three practical indication buckets:

1. General skin wound treatment (Claim 1): burn/ulcer/skin graft
2. Ulcer subgrouping (Claims 2-3): decubitus ulcer or diabetic ulcer
3. Burn subgroup and burn-associated physiology (Claims 11 and 12-20): burn-induced weight loss treated with oxandrolone plus a protein supplement

How broad are the route-of-administration limits?

Claim 1 requires “administering orally or topically.” That is a two-route limitation:

• Oral administration is within claim scope.
• Topical administration is within claim scope.
• The patent does not explicitly include parenteral routes (IV/IM/SC) in the claims provided, so those uses are outside the literal scope unless other claims or equivalents are argued.

How strong is the “therapeutically effective amount” constraint?

Claim 1 uses “therapeutically effective amount,” which is a functional limitation. Dependent claims add numeric and formulation constraints, tightening certainty and reducing interpretive risk:

• Claims 5-7 narrow to about 1-100 mg/day; exemplars include about 20 mg/day and about 80 mg/day.
• Claims 8-10 specify dosage form categories (solid, liquid, sustained-release).

From an infringement-risk perspective, any commercial or clinical protocol that hits the numeric range and binds to the wound indication and route is closer to literal infringement.

What wound types are explicitly claimed?

• Burn: covered in Claim 1 via the group selection and specifically recited in Claim 11.
• Ulcer: covered in Claim 1 via the group selection and specifically recited in Claims 2-3.
• Decubitus ulcer: explicitly recited (Claim 3).
• Diabetic ulcer: explicitly recited (Claim 3).
• Skin graft: explicitly recited in Claim 1.

What dosage range does the patent claim?

Dependent Claims 5-7 set the numeric boundaries:

• About 1-100 mg per day (Claim 5)
• About 20 mg per day (Claim 6)
• About 80 mg per day (Claim 7)

These “about” qualifiers typically preserve some tolerance around the stated values. The enforceable scope expands with any practice that falls inside the “about” region for these exemplars, and at least partially inside the “about 1-100 mg/day” band for Claim 5.

How do the dosage form and release-rate limitations work?

Dependent Claims 8-10 split dosage form variants:

• Solid dosage form (Claim 8)
• Liquid dosage form (Claim 9)
• Sustained-release formulation (Claim 10)

If an accused regimen uses sustained-release delivery, Claim 10 is directly implicated if all other elements are met (wound type and route and therapeutically effective dosing). Solid and liquid variants create additional independent claim hooks against formulation-specific competition.

What formulations and product types are captured by the claims of US 6,576,659?

This patent is not limited to a single pharmaceutical form of oxandrolone; the claim set explicitly supports multiple presentation types.

Does the patent require a specific oxandrolone formulation?

No single formulation is required in Claim 1. However, dependent claims create different “product posture” hooks:

• If a competitor uses sustained-release, Claim 10 is implicated.
• If a competitor uses solid or liquid, Claims 8 or 9 are implicated, respectively.

Practically, that means a formulation design-around that only changes the physical form (solid vs liquid vs sustained release) may still fall within the patent, unless it moves entirely outside the constrained categories or outside route and dosing ranges.

Oral versus topical formulation exposure

Because Claim 1 includes both oral and topical administration, competitors face exposure on two fronts:

• Oral oxandrolone protocols used for wound treatment are within Claim 1 scope if all additional elements align.
• Topical oxandrolone preparations used for wound treatment are within Claim 1 scope if the topical use is in the claimed contexts (burn/ulcer/skin graft) and dosing is within the therapeutically effective and, if applicable, numeric ranges.

What is the role of “sustained-release” in claim strength?

“Sustained-release” is often interpreted as a structural/functional delivery profile rather than a marketing label. Claim 10 gives the patent a path to capture:

• controlled-release tablets/capsules
• depot or extended-release oral forms
• extended-release topical delivery systems (depending on how “sustained-release formulation” is construed and supported by evidence)

If a competitor shifts delivery away from sustained release to immediate release, it may weaken Claim 10 but does not avoid Claims 1-9 if sustained release is not required elsewhere.

What is the scope of claim 12 “burn-induced weight loss” with oxandrolone plus protein supplement?

Claim 12 is a distinct method-of-treatment branch that expands beyond wound healing to a burn-associated systemic outcome:

• Treating “burn-induced weight loss” in a burn patient
• Requires administering therapeutically effective amount of oxandrolone
• Requires “in conjunction with a protein supplement”

What elements are mandatory in claim 12?

Compared with Claim 1, claim 12 introduces additional mandatory elements:

1. The patient must be a “burn patient” with burn-induced weight loss
2. Oxandrolone administered orally or topically
3. Protein supplement co-administered “in conjunction with” oxandrolone

How does protein-supplement wording affect enforceability?

The phrase “in conjunction with a protein supplement” is a combination limitation. In infringement analysis, that typically raises the evidentiary bar because an accused activity must show the protein supplement is part of the same therapeutic regimen used with oxandrolone for the burn-induced weight loss treatment.

Does claim 12 restrict dosage and formulation like claim 1?

Yes, dependent claims mirror Claim 1’s dependent structure:

• About 1-100 mg/day (Claim 13)
• About 20 mg/day (Claim 14)
• About 80 mg/day (Claim 15)
• Oral administration (Claim 16)
• Topical administration (Claim 17)
• Solid (Claim 18)
• Liquid (Claim 19)
• Sustained-release (Claim 20)

So once the burn-induced weight loss + protein supplement step is satisfied, the numeric and dosage-form constraints become additional attack points and can narrow or widen infringement depending on the accused protocol.

How many US patents likely cover these oxandrolone wound-use concepts, and where does 6,576,659 sit?

Only one patent number is provided (US 6,576,659) and no Orange Book, prosecution history, or family data were provided. With that constraint, a complete cross-patent count across the entire oxandrolone wound-use space cannot be produced without risking factual error.

What can be stated strictly from the claim set provided:

• 6,576,659 is explicitly a method-of-treatment patent with multiple clinical subtopics (burn/wound healing and burn-induced weight loss).
• It likely competes in enforceability against later patents directed to oxandrolone wound healing, oxandrolone ulcer healing, and oxandrolone burn nutrition/weight-management regimens, but no reliable enumeration is possible here.

How does US 6,576,659 compare with typical oxandrolone IP patterns (composition vs method, route, dosing, and indication)?

Within anabolic-androgenic steroid IP landscapes, two common claim archetypes appear:

1. Composition formulation (how oxandrolone is made/delivered)
2. Method of use (specific patient conditions and regimens)

US 6,576,659 is squarely in category 2 and is designed to catch:

• clinicians following a treatment protocol using oxandrolone for specific wound types
• companies whose product instructions, labeling, or commercialization strategy induces use matching the claims
• manufacturers whose product design supports the route (oral vs topical) and dosage form (solid/liquid/sustained release)

Because method claims are indication- and regimen-dependent, the enforceability focus is the intersection of:

• “wound selection” (burn/ulcer/skin graft)
• route (oral/topical)
• dosing range (when dependent claims are asserted)
• co-therapy (protein supplement for burn-induced weight loss)

When does US 6,576,659 lose exclusivity, and what timeline matters for generic entry?

No patent filing date, issue date, expiration schedule, term adjustments, or terminal disclaimers were provided. Without that data, any exclusivity timeline or generic entry projection would risk being wrong.

What patent litigation risks exist for oxandrolone wound methods under US 6,576,659?

No litigation docket, settlement agreement, or Paragraph IV history is provided. A litigation posture analysis cannot be generated reliably from the claim text alone.

What is the Orange Book status of oxandrolone for wound indications under US 6,576,659?

Orange Book status requires linkages between this patent and a specific FDA-approved drug product and NDA/ANDA listing. No Orange Book listing details were provided, so an accurate mapping cannot be produced.

What generic entry risks exist if oxandrolone is used off-label for skin wound indications?

Method patents often face a practical reality: enforcement typically depends on the accused activity aligning with the claimed method elements. Based solely on the claim structure:

• Generic manufacturers selling oxandrolone for broader indications can still face exposure if their commercial activity, labeling, or instructions promote wound healing uses that match the claims.
• Off-label use by prescribers can create risk if the prescriber conduct is proven to match every claim element (wound selection, route, dosing, and protein-supplement condition for claim 12).

A design-around that changes only formulation may not eliminate claim coverage because the claims already encompass solid, liquid, and sustained-release categories.

Jurisdictional scope: is US 6,576,659 limited to US conduct?

A US patent enforces against US acts of infringement and offers leverage tied to US regulatory conduct. Cross-border protection depends on foreign family members, which were not provided, so an international landscape cannot be stated here.

Commercial exposure: which oxandrolone use cases map most directly to US 6,576,659?

Direct mapping to the claim set is straightforward:

• Oxandrolone regimens used to treat burns, ulcers, or skin graft-related wounds, administered orally or topically, with therapeutically effective dosing.
• Oxandrolone regimens used specifically for decubitus ulcer or diabetic ulcer, orally or topically.
• Burn-induced weight loss regimens in burn patients using oxandrolone together with a protein supplement, orally or topically, with attention to dose and dosage form.

Key takeaways

• US 6,576,659 is a method-of-treatment patent for oxandrolone, covering skin wound types (burn, ulcer, skin graft) with oral or topical administration.
• Dependent claims add enforceability hooks: ulcer subtype (decubitus, diabetic), numeric dosing (about 1-100 mg/day; about 20 and 80 mg/day), and dosage forms (solid, liquid, sustained-release).
• Claim 12 creates a separate combination regimen: oxandrolone plus a protein supplement to treat burn-induced weight loss in a burn patient.
• Because the claims require specific wound/weight-loss contexts and (for claim 12) a protein supplement co-therapy, risk concentrates on direct clinical regimens that match the full element set.

FAQs

1. Does US 6,576,659 cover intravenous administration of oxandrolone for wound healing?
   The provided claims require “administering orally or topically,” so IV/IM/SC administration is not covered by the claim text supplied.

2. Is the “therapeutically effective amount” limit in claim 1 tied to any specific dose?
   Claim 1 uses a functional “therapeutically effective amount.” Numeric dose constraints appear only in dependent claims (about 1-100 mg/day; exemplars 20 mg/day and 80 mg/day).

3. Can oxandrolone topical creams for diabetic ulcers fall within US 6,576,659?
   Yes, if the use matches claim 1 (ulcer selection) and the dependent ulcer subtype (diabetic ulcer in claim 3) and uses topical administration with therapeutically effective dosing.

4. What additional requirement makes claim 12 harder to design around than claim 1?
   Claim 12 requires co-administration “in conjunction with a protein supplement,” which is a combination regimen limitation absent from claim 1.

5. Is sustained-release explicitly required for infringement of all claims?
   No. Sustained-release is only in dependent Claim 10 (and in the mirrored dependent set for claim 12 via Claim 20). The independent claim 1 does not require sustained release.

References

No external sources were used because only the claim text and a single US patent number were provided.